Vanda Pharmaceuticals (VNDA) Change in Cash (2010 - 2026)

Vanda Pharmaceuticals has disclosed Change in Cash across 17 years of filings, most recently posting -$30.8 million for Q1 2026.

• Change in Cash for Q1 2026 came in at -$30.8 million, down 425.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$57.8 million (down 332.29% YoY), and the FY2025 annual result was -$17.5 million, up 47.87% from the prior year.
• Change in Cash came in at -$30.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $14.8 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $219.1 million in Q1 2023 to a low of -$204.1 million in Q2 2023.
• The 5-year median for Change in Cash is -$8.7 million (2022), against an average of $112529.4.
• Across the five-year window, Change in Cash surged 5428.21% in 2022 and tumbled 2245.63% in 2023, its largest moves.
• Vanda Pharmaceuticals' Change in Cash stood at $85.6 million in 2022, then slumped by 155.31% to -$47.4 million in 2023, then jumped by 103.84% to $1.8 million in 2024, then jumped by 715.23% to $14.8 million in 2025, then sank by 307.82% to -$30.8 million in 2026.
• The last three Change in Cash figures came in at -$30.8 million (Q1 2026), $14.8 million (Q4 2025), and -$11.0 million (Q3 2025), per Business Quant data.